docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2022-21-6-29-34docru-45Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYНовые международные рекомендации по ведению пациентов с гастроэзофагеальной рефлюксной болезнью: диагностика и лечение типичных синдромовCurrent International Guidelines for the Management of Patients with Gastroesophageal Reflux Disease: Diagnosis and Management of Typical Syndromeshttps://orcid.org/0000-0002-9980-2294ЦукановВ. В.TsukanovV. V.

Цуканов Владислав Владимирович - д. м. н., профессор, заведующий клиническим отделением патологии пищеварительной системы у взрослых и детей

660022, г. Красноярск, ул. Партизана Железняка, д. 3г

3-g Partisan Zheleznyak Str., Krasnoyarsk, 660022

gastro@impn.ruhttps://orcid.org/0000-0002-6481-3196ВасютинА. В.VasyutinA. V.

Васютин Александр Викторович - к. м. н., старший научный сотрудник клинического отделения патологии пищеварительной системы у взрослых и детей

660022, г. Красноярск, ул. Партизана Железняка, д. 3г.

3-g Partisan Zheleznyak Str., Krasnoyarsk, 660022

alexander@kraslan.ruhttps://orcid.org/0000-0001-7518-1895ТонкихЮ. Л.TonkikhYu. L.

Тонких Юлия Леонгардовна - к. м. н., ведущий научный сотрудник клинического отделения патологии пищеварительной системы у взрослых и детей

660022, г. Красноярск, ул. Партизана Железняка, д. 3г.

3-g Partisan Zheleznyak Str., Krasnoyarsk, 660022

tjulia@bk.ruФГБНУ «Федеральный исследовательский центр «Красноярский научный центр» Сибирского отделения Российской академии наук» обособленное подразделение «Научно-исследовательский институт медицинских проблем Севера»РоссияScientific and Research Institute of Medical Problems of the North of the Federal Research Centre “Krasnoyarsk Scientific Centre of the Siberian Branch of the Russian Academy of Science”Russian FederationScientific and Research Institute of Medical Problems of the North of the Federal Research Centre “Krasnoyarsk Scientific Centre of the Siberian Branch of the Russian Academy of Science”Russian Federation202214022025216ТЕРАПИЯ2934Copyright © Цуканов В.В., Васютин А.В., Тонких Ю.Л., 20252025Цуканов В.В., Васютин А.В., Тонких Ю.Л.Tsukanov V.V., Vasyutin A.V., Tonkikh Y.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/45

Цель обзора: проанализировать клинические рекомендации Американской коллегии гастроэнтерологии 2022 г. по диагностике и лечению гастроэзофагеальной рефлюксной болезни (ГЭРБ).Основные положения. При диагностике ГЭРБ имеют значение эмпирическое назначение ингибиторов протонной помпы (ИПП), анализ симптомов, эзофагогастродуоденоскопия, pH-импедансометрия и манометрия высокого разрешения. Основными методами терапии типичных синдромов ГЭРБ являются коррекция питания, снижение массы тела и прием ИПП. У пациентов с неэрозивной рефлюксной болезнью после достижения ответа на лечение можно прекратить их прием или перейти на терапию по требованию. У больных с эзофагитом стадий C и D целесообразно длительное поддерживающее лечение ИПП.Заключение. Рекомендации Американской коллегии гастроэнтерологии содержат целый ряд важных положений, которые будут полезны практическим врачам. Однако клинико-эпидемиологическая ситуация в России очень существенно отличается от таковой в западных странах, и это необходимо учитывать при определении тактики ведения пациентов с ГЭРБ.

Objective of the Review: Analysis of the 2022 American College of Gastroenterology clinical guidelines for the diagnosis and treatment of gastroesophageal reflux disease (GERD).Key points. Empiric proton pump inhibitors (PPIs), symptom analysis, esophagogastroduodenoscopy, pH-impedancemetry, and highresolution manometry are important in the diagnosis of GERD. The main therapies for typical GERD syndromes are dietary modification, weight loss, and PPIs. In patients with non-erosive reflux disease, once a response to treatment has been achieved, PPIs may be discontinued or switched to on-demand PPI therapy. In patients with stage C and D esophagitis, long-term maintenance treatment with a PPI is appropriate.Conclusion. The recommendations of the American College of Gastroenterology contain a number of important provisions that will be useful to practitioners. However, the clinical and epidemiological situation in Russia is very different from that in Western countries, and this must be taken into account when determining the tactics of managing patients with GERD.

гастроэзофагеальная рефлюксная болезньэрозивный эзофагитдиагностикалечениеgastroesophageal reflux diseaseerosive esophagitisdiagnosistreatmentReferencesDelshad S.D., Almario C.V., Chey W.D., Spiegel B.M.R. Prevalence of gastroesophageal reflux disease and proton pump inhibitorrefractory symptoms. Gastroenterology. 2020; 158(5): 1250–61.e2. DOI: 10.1053/j.gastro.2019.12.014Delshad S.D., Almario C.V., Chey W.D., Spiegel B.M.R. Prevalence of gastroesophageal reflux disease and proton pump inhibitorrefractory symptoms. Gastroenterology. 2020; 158(5): 1250–61.e2. DOI: 10.1053/j.gastro.2019.12.014Kahrilas P.J., Boeckxstaens G., Smout A.J. Management of the patient with incomplete response to PPI therapy. Best Pract. Res. Clin. Gastroenterol. 2013; 27(3): 401–14. DOI: 10.1016/j.bpg.2013.06.005Kahrilas P.J., Boeckxstaens G., Smout A.J. Management of the patient with incomplete response to PPI therapy. Best Pract. Res. Clin. Gastroenterol. 2013; 27(3): 401–14. DOI: 10.1016/j.bpg.2013.06.005Yadlapati R., Pandolfino J.E. Personalized approach in the work-up and management of gastroesophageal reflux disease. Gastrointest. Endosc. Clin. N. Am. 2020; 30(2): 227–38. DOI: 10.1016/j.giec.2019.12.002Yadlapati R., Pandolfino J.E. Personalized approach in the work-up and management of gastroesophageal reflux disease. Gastrointest. Endosc. Clin. N. Am. 2020; 30(2): 227–38. DOI: 10.1016/j.giec.2019.12.002Cremonini F., Wise J., Moayyedi P., Talley N.J. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am. J. Gastroenterol. 2005; 100(6): 1226–32. DOI: 10.1111/j.1572-0241.2005.41657.xCremonini F., Wise J., Moayyedi P., Talley N.J. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am. J. Gastroenterol. 2005; 100(6): 1226–32. DOI: 10.1111/j.1572-0241.2005.41657.xKahrilas P.J., Hughes N., Howden C.W. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut. 2011; 60(11): 1473–8. DOI: 10.1136/gut.2011.241307Kahrilas P.J., Hughes N., Howden C.W. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut. 2011; 60(11): 1473–8. DOI: 10.1136/gut.2011.241307Lundell L.R., Dent J., Bennett J.R., Blum A.L. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999; 45(2): 172–80. DOI: 10.1136/gut.45.2.172Lundell L.R., Dent J., Bennett J.R., Blum A.L. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999; 45(2): 172–80. DOI: 10.1136/gut.45.2.172Gyawali C.P., Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018; 154(2): 302–18. DOI: 10.1053/j.gastro.2017.07.049Gyawali C.P., Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018; 154(2): 302–18. DOI: 10.1053/j.gastro.2017.07.049Dunbar K.B., Agoston A.T., Odze R.D., Huo X. et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA. 2016; 315(19): 2104–12. DOI: 10.1001/jama.2016.5657Dunbar K.B., Agoston A.T., Odze R.D., Huo X. et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA. 2016; 315(19): 2104–12. DOI: 10.1001/jama.2016.5657Odiase E., Schwartz A., Souza R.F., Martin J. et al. New eosinophilic esophagitis concepts call for change in proton pump inhibitor management before diagnostic endoscopy. Gastroenterology. 2018; 154(5): 1217–21.e3. DOI: 10.1053/j.gastro.2018.03.003Odiase E., Schwartz A., Souza R.F., Martin J. et al. New eosinophilic esophagitis concepts call for change in proton pump inhibitor management before diagnostic endoscopy. Gastroenterology. 2018; 154(5): 1217–21.e3. DOI: 10.1053/j.gastro.2018.03.003Stoikes N., Drapekin J., Kushnir V., Shaker A. et al. The value of multiple rapid swallows during preoperative esophageal manometry before laparoscopic antireflux surgery. Surg. Endosc. 2012; 26(12): 3401–7. DOI: 10.1007/s00464-012-2350-0Stoikes N., Drapekin J., Kushnir V., Shaker A. et al. The value of multiple rapid swallows during preoperative esophageal manometry before laparoscopic antireflux surgery. Surg. Endosc. 2012; 26(12): 3401–7. DOI: 10.1007/s00464-012-2350-0Kaltenbach T., Crockett S., Gerson L.B. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch. Intern. Med. 2006; 166(9): 965–71. DOI: 10.1001/archinte.166.9.965Kaltenbach T., Crockett S., Gerson L.B. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch. Intern. Med. 2006; 166(9): 965–71. DOI: 10.1001/archinte.166.9.965Khoury R.M., Camacho-Lobato L., Katz P.O., Mohiuddin M.A. et al. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 1999; 94(8): 2069–73. DOI: 10.1111/j.1572-0241.1999.01279.xKhoury R.M., Camacho-Lobato L., Katz P.O., Mohiuddin M.A. et al. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 1999; 94(8): 2069–73. DOI: 10.1111/j.1572-0241.1999.01279.xAllampati S., Lopez R., Thota P.N., Ray M. et al. Use of a positional therapy device significantly improves nocturnal gastroesophageal reflux symptoms. Dis. Esophagus. 2017; 30(3): 1–7. DOI: 10.1111/dote.12495Allampati S., Lopez R., Thota P.N., Ray M. et al. Use of a positional therapy device significantly improves nocturnal gastroesophageal reflux symptoms. Dis. Esophagus. 2017; 30(3): 1–7. DOI: 10.1111/dote.12495Person E., Rife C., Freeman J., Clark A. et al. A novel sleep positioning device reduces gastroesophageal reflux: a randomized controlled trial. J. Clin. Gastroenterol. 2015; 49(8): 655–9. DOI: 10.1097/MCG.0000000000000359Person E., Rife C., Freeman J., Clark A. et al. A novel sleep positioning device reduces gastroesophageal reflux: a randomized controlled trial. J. Clin. Gastroenterol. 2015; 49(8): 655–9. DOI: 10.1097/MCG.0000000000000359Newberry C., Lynch K. The role of diet in the development and management of gastroesophageal reflux disease: why we feel the burn. J. Thorac. Dis. 2019; 11(suppl.12): S1594–601. DOI: 10.21037/jtd.2019.06.42Newberry C., Lynch K. The role of diet in the development and management of gastroesophageal reflux disease: why we feel the burn. J. Thorac. Dis. 2019; 11(suppl.12): S1594–601. DOI: 10.21037/jtd.2019.06.42Ness-Jensen E., Lindam A., Lagergren J., Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study. Am. J. Gastroenterol. 2014; 109(2): 171–7. DOI: 10.1038/ajg.2013.414Ness-Jensen E., Lindam A., Lagergren J., Hveem K. Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population-based cohort study: the HUNT study. Am. J. Gastroenterol. 2014; 109(2): 171–7. DOI: 10.1038/ajg.2013.414Kohata Y., Fujiwara Y., Watanabe T., Kobayashi M. et al. Longterm benefits of smoking cessation on gastroesophageal reflux disease and health-related quality of life. PLoS One. 2016; 11(2): e0147860. DOI: 10.1371/journal.pone.0147860Kohata Y., Fujiwara Y., Watanabe T., Kobayashi M. et al. Longterm benefits of smoking cessation on gastroesophageal reflux disease and health-related quality of life. PLoS One. 2016; 11(2): e0147860. DOI: 10.1371/journal.pone.0147860Wang W.H., Huang J.Q., Zheng G.F., Xia H.H. et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J. Gastroenterol. 2005; 11(26): 4067–77. DOI: 10.3748/wjg.v11.i26.4067Wang W.H., Huang J.Q., Zheng G.F., Xia H.H. et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J. Gastroenterol. 2005; 11(26): 4067–77. DOI: 10.3748/wjg.v11.i26.4067Khan M., Santana J., Donnellan C., Preston C. et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst. Rev. 2007; 2: CD003244. DOI: 10.1002/14651858.CD003244.pub2Khan M., Santana J., Donnellan C., Preston C. et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst. Rev. 2007; 2: CD003244. DOI: 10.1002/14651858.CD003244.pub2Hatlebakk J.G., Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacokinet. 1996; 31(5): 386–406. DOI: 10.2165/00003088-199631050-00005Hatlebakk J.G., Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacokinet. 1996; 31(5): 386–406. DOI: 10.2165/00003088-199631050-00005Lee R.D., Mulford D., Wu J., Atkinson S.N. The effect of time-ofday dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment. Pharmacol. Ther. 2010; 31(9): 1001–11. DOI: 10.1111/j.1365-2036.2010.04272.xLee R.D., Mulford D., Wu J., Atkinson S.N. The effect of time-ofday dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment. Pharmacol. Ther. 2010; 31(9): 1001–11. DOI: 10.1111/j.1365-2036.2010.04272.xGunaratnam N.T., Jessup T.P., Inadomi J., Lascewski D.P. Suboptimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2006; 23(10): 1473–7. DOI: 10.1111/j.1365-2036.2006.02911.xGunaratnam N.T., Jessup T.P., Inadomi J., Lascewski D.P. Suboptimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2006; 23(10): 1473–7. DOI: 10.1111/j.1365-2036.2006.02911.xSavarino V., Marabotto E., Zentilin P., Furnari M. et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev. Clin. Pharmacol. 2020; 13(4): 437–49. DOI: 10.1080/17512433.2020.1752664Savarino V., Marabotto E., Zentilin P., Furnari M. et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev. Clin. Pharmacol. 2020; 13(4): 437–49. DOI: 10.1080/17512433.2020.1752664Boghossian T.A., Rashid F.J., Thompson W., Welch V. et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst. Rev. 2017; 3(3): CD011969. DOI: 10.1002/14651858.CD011969.pub2Boghossian T.A., Rashid F.J., Thompson W., Welch V. et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst. Rev. 2017; 3(3): CD011969. DOI: 10.1002/14651858.CD011969.pub2Talley N.J., Lauritsen K., Tunturi-Hihnala H., Lind T. et al. Esomeprazole 20 mg maintains symptom control in endoscopynegative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment. Pharmacol. Ther. 2001; 15(3): 347–54. DOI: 10.1046/j.1365-2036.2001.00943.xTalley N.J., Lauritsen K., Tunturi-Hihnala H., Lind T. et al. Esomeprazole 20 mg maintains symptom control in endoscopynegative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment. Pharmacol. Ther. 2001; 15(3): 347–54. DOI: 10.1046/j.1365-2036.2001.00943.xSchindlbeck N.E., Klauser A.G., Berghammer G., Londong W. et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut. 1992; 33(8): 1016–9. DOI: 10.1136/gut.33.8.1016Schindlbeck N.E., Klauser A.G., Berghammer G., Londong W. et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut. 1992; 33(8): 1016–9. DOI: 10.1136/gut.33.8.1016Lind T., Havelund T., Lundell L., Glise H. et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis — a placebo-controlled randomized trial. Aliment. Pharmacol. Ther. 1999; 13(7): 907–14. DOI: 10.1046/j.1365-2036.1999.00564.xLind T., Havelund T., Lundell L., Glise H. et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis — a placebo-controlled randomized trial. Aliment. Pharmacol. Ther. 1999; 13(7): 907–14. DOI: 10.1046/j.1365-2036.1999.00564.xPace F., Tonini M., Pallotta S., Molteni P. et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment. Pharmacol. Ther. 2007; 26(2): 195–204. DOI: 10.1111/j.1365-2036.2007.03381.xPace F., Tonini M., Pallotta S., Molteni P. et al. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'. Aliment. Pharmacol. Ther. 2007; 26(2): 195–204. DOI: 10.1111/j.1365-2036.2007.03381.xInadomi J.M., Jamal R., Murata G.H., Hoffman R.M. et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001; 121(5): 1095–100. DOI: 10.1053/gast.2001.28649Inadomi J.M., Jamal R., Murata G.H., Hoffman R.M. et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001; 121(5): 1095–100. DOI: 10.1053/gast.2001.28649Juul-Hansen P., Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopynegative reflux disease. Is rebound hypersecretion of acid a problem? Scand. J. Gastroenterol. 2011; 46(4): 398–405. DOI: 10.3109/00365521.2010.537684Juul-Hansen P., Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopynegative reflux disease. Is rebound hypersecretion of acid a problem? Scand. J. Gastroenterol. 2011; 46(4): 398–405. DOI: 10.3109/00365521.2010.537684Metz D.C., Pilmer B.L., Han C., Perez M.C. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am. J. Gastroenterol. 2011; 106(11): 1953–60. DOI: 10.1038/ajg.2011.220Metz D.C., Pilmer B.L., Han C., Perez M.C. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am. J. Gastroenterol. 2011; 106(11): 1953–60. DOI: 10.1038/ajg.2011.220Tsukanov V.V., Butorin N.N., Maady A.S., Shtygasheva O.V. et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia. Helicobacter. 2011; 16(2): 107–12. DOI: 10.1111/j.1523-5378.2011.00827.xTsukanov V.V., Butorin N.N., Maady A.S., Shtygasheva O.V. et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia. Helicobacter. 2011; 16(2): 107–12. DOI: 10.1111/j.1523-5378.2011.00827.xTsukanov V.V., Kasparov E.V., Tonkikh J.L., Shtygasheva O.V. et al. Peptic ulcer disease and Helicobacter pylori infection in different Siberian ethnicities. Helicobacter. 2017; 22(1): e12322. DOI: 10.1111/hel.12322Tsukanov V.V., Kasparov E.V., Tonkikh J.L., Shtygasheva O.V. et al. Peptic ulcer disease and Helicobacter pylori infection in different Siberian ethnicities. Helicobacter. 2017; 22(1): e12322. DOI: 10.1111/hel.12322

The authors declare that there are no conflicts of interest present.